Learn how Series 27 removes nonallowable assets, adjusts net worth, and applies operational deductions before final net capital.
After minimum capital and aggregate indebtedness are framed, Series 27 turns to the balance sheet itself. This is where the FINOP decides what really counts as usable regulatory value. Some assets are readily convertible to cash. Others are too uncertain, too slow, too contingent, or too operationally risky to receive full credit. That is why this topic feels like accounting mixed with skepticism.
The best way to study it is to remember that net capital is more conservative than book value. If an item cannot reliably support the firm in stress, the rules often reduce or eliminate its value. That is why aged receivables, fixed assets, unsecured claims, nonmarketable items, fidelity-bond deductible issues, and securities differences appear together in the same lesson. They are all places where accounting value and regulatory value split apart.
| Line item or issue | What the FINOP should ask | Typical regulatory effect |
|---|---|---|
| Readily available cash items | Can the firm access and use the item promptly? | Often remains allowable if there is no separate restriction. |
| Fixed assets and prepaid items | Does the item help the firm meet capital needs today? | Often treated as nonallowable or excluded from usable capital. |
| Aged or unsecured receivables | Is collection uncertain or too slow to rely on? | Often requires a deduction or reduced treatment. |
| Nonmarketable or restricted assets | Could the item be monetized quickly at a reliable value? | Often removed from allowable capital support. |
| Operational differences and unresolved breaks | Does the item show that the firm’s records or control environment may be overstating value? | Often results in a deduction until resolved. |
| Fidelity-bond deductible and similar exposures | Has the firm retained a risk that should reduce the capital cushion? | Often creates a required deduction from net capital. |
The exam usually rewards the candidate who asks whether the item is truly liquid, reliable, and properly documented rather than merely present on the balance sheet.
[ \text{Net Capital} \approx \text{Net Worth} - \text{Nonallowable Assets} - \text{Operational Charges} - \text{Other Required Deductions} ]
This is not a full legal formula for every scenario, but it captures the Series 27 instinct: start from reported equity and then strip out what the rules do not trust enough to count.
flowchart TD
A["Identify the balance-sheet item or operational difference"] --> B{"Is it readily available and reliable as capital support?"}
B -- "Yes" --> C{"Does a specific rule still require an adjustment or deduction?"}
B -- "No" --> D["Treat as nonallowable or subject to deduction"]
C -- "No" --> E["Keep the item in the allowable analysis"]
C -- "Yes" --> F["Apply the required net-worth adjustment or deduction"]
D --> G["Document why book value and regulatory value differ"]
F --> G
E --> G
This is the logic Series 27 wants from the FINOP. It is not enough to know that an item exists. The question is whether the firm can truly lean on it in a regulatory capital framework.
A broker-dealer has a balance-sheet asset that is valid under GAAP but cannot be readily converted into cash and offers little immediate support to the firm’s financial-responsibility position. How will Series 27 most likely treat that item?
A. As automatically exempt from any adjustment because it is a booked asset
B. As likely nonallowable or otherwise subject to deduction from usable capital
C. As part of aggregate indebtedness rather than as an asset
D. As evidence that the firm qualifies for lower minimum capital
Correct answer: B.
This section tests the gap between accounting value and regulatory value. A real asset can still be too weak or illiquid to support net capital fully.